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Introduction
Gout is an inflammatory arthritis caused by the deposition 
of monosodium urate (MSU) crystals in and around 
joints, which occurs against a background of chronic 
hyperuricaemia. It is recognised as one of the oldest 
diseases afflicting man, dating back to ancient Egypt, 
2640 BC. More than 2 500 years ago, Hippocrates dubbed 
it “the unwalkable disease”.1 Today, despite advances in our 
understanding of the pathophysiology of the disease, and 
the availability of inexpensive, effective treatment, gout still 
remains a major cause of disability.2
Gout is the most common cause of inflammatory arthritis 
in men over 40 years of age, while the prevalence in 
postmenopausal women continues to rise.3,4 With the 
growing pervasiveness of the disease and mounting 
recognition of its association with cardiovascular morbidity 
and mortality, it is imperative to recognise and treat these 
patients early.4,5 Recurrent attacks of acute arthritis, if not 
treated appropriately, eventually lead to chronic destructive 
arthropathy, tophi and renal disease. This impacts on the 
quality of life of the patient, while decreased productivity 
leads to an increased burden on economies and managed 
care services. Gout accounts for six per cent of the total 
healthcare costs relating to the elderly.6 Most of the 
deformity and disability of this potentially curable disease 
can be attributed to suboptimal management. Primarily, 
this stems from poor patient education and compliance, 
under-utilisation of available drugs, drug interactions and 
co-morbidities. Current management guidelines address 
these problems and aim to assist in patient care. 
The increasing burden of gout, coupled with the 
development of novel, innovative therapies has renewed 
interest in this often trivialised medical condition. The 
family practitioner is at the forefront of diagnosis and gout 
management. Rheumatologists are involved in < 2% of 
cases.7 This review aims to provide a practical approach to 
the diagnosis and management of gout in the primary care 
setting, and highlights vigilance of the at-risk population 
and the importance of cardiovascular morbidity in these 
patients. 
A rising prevalence: the population at 
risk 
Epidemiological studies conducted in several countries 
suggest that the prevalence of gout is on the rise. Currently, 
Gouty arthritis: an approach for general practice
Tikly M, MBBCh, PhD, FCP(SA), FRCP, Professor of Rheumatology
Makan K, MBChB, FCP(SA), Rheumatology Fellow 
Division of Rheumatology, Chris Hani Baragwanath Hospital; University of the Witwatersrand
Correspondence to: Mohammed Tikly, e-mail: mohammed.tikly@wits.ac.za
Keywords: gout, gouty arthritis, hyperuricaemia, monosodium urate, disability
Abstract
Gout is a common crystal-induced inflammatory arthritis, the prevalence and clinical complexity of which is increasing in 
the face of a growing aged population with multiple co-morbidities. Recent epidemiological studies emphasise that lifestyle 
factors strongly influence the development of hyperuricaemia and gout. Moreover, there is growing evidence that gout is 
an independent risk factor for cardiovascular disease. Acute attacks of gout are extremely painful and disabling, and if 
repeated attacks go untreated, chronic deforming arthritis ensues. Early diagnosis and appropriate therapy is essential to 
reduce long-term disability. Identification of monosodium urate crystals on synovial fluid analysis is the gold standard in gout 
diagnosis. Nonsteroidal anti-inflammatory drugs and oral or intra-articular corticosteroids remain central to the treatment of 
acute attacks. Prophylactic colchicine use, during the intercritical period, reduces gout flares, a common complication on 
initiation of urate-lowering therapy (ULT). Allopurinol is the treatment of choice when ULT is indicated. Gout management is 
suboptimal in many patients because of non-adherence to treatment and underutilisation of available treatments. Treating to 
target: a serum uric acid level < 0.35mmol/l, prevents crystal deposition in joints and soft tissues, thereby preventing acute 
attacks and ongoing inflammation, as well as decreasing the size and number of tophi. Treatment strategies should include 
attention to cardiovascular risk. The family practitioner is paramount to gout management which should be individualised. 
Emphasis should be placed on ongoing education and prevention.
 Peer reviewed. (Submitted: 2012-08-13. Accepted: 2012-11-18.) © SAAFP S Afr Fam Pract 2013;55(4):307-312
CPD Article: Gouty arthritis: an approach for general practice
308 Vol 55 No 4S Afr Fam Pract 2013
it is estimated to affect 1-2% of the population worldwide, 
although higher rates have been reported in certain 
populations. In the US alone, there are an estimated 6-8 
million people with a lifetime history of gout.3-5 In South 
Africa, where gout was once thought to be uncommon, 
there is a noticeable increase.8,9 Men are affected more 
than women. Older age confers greater risk in both gender 
groups.3-5
The growing epidemic has been attributed to diet and 
lifestyle changes as a consequence of urbanisation, as 
well as an increasing ageing population. The aged gout 
population has multiple co-morbidities and this has added 
to the clinical complexity of the disease.3-5 
The role that is played by diet and lifestyle, as risk factors 
for gout, has been known for a long time. Hence, gout 
was often dubbed the “disease of kings”.1 Recent large 
population-based studies have confirmed that purine-rich 
foods such as red meat, seafood (particularly shellfish), and 
alcoholic beverages (especially beer with its high guanosine 
content, and spirits to a lesser extent), confer a high risk 
of gout. Fructose-sweetened drinks are also a significant 
risk factor. Conversely, low-fat dairy (particularly yoghurt), 
coffee intake, high doses of vitamin C and vegetable purines 
derived from lentils and wine have a neutral effect.3-5
Some commonly used medications can cause 
hyperuricaemia and cause or precipitate gout. These 
include diuretics, thiazides and loop diuretics, low-dose 
aspirin, cyclosporine (in transplant patients), and the anti-
tubuerculosis agents, pyrazinamide and ethambutol. 
Diuretics have been implicated as the leading cause of 
secondary gout in postmenopausal women and are a 
common trigger of acute gout. The associations tend to be 
stronger with longer use and higher doses.3-5,10,11
Although not an absolute risk factor for gout, there is a 
propensity for MSU crystals to deposit on osteoarthritic 
cartilage. Similar joint sites are involved in both gout and 
osteoarthritis and are unaffected by disease duration. This 
suggests that this is not a secondary phenomenon.3-5
There is also a strong genetic predisposition for gout 
in some cases. Polymorphisms of genes, encoding for 
specialised urate transporters within the renal proximal 
tubules implicated in the reabsorption of urate [urate 
transporter 1 (URAT1) and glucose transporter T9 (GLUT9], 
have been associated with hyeruricaemia and gout.3-5,12
Gout commonly occurs in the setting of the metabolic 
syndrome. Its component features are hypertension, obesity, 
dyslipidaemia, insulin resistance or type 2 diabetes, and 
renal and cardiovascular disease. A body mass index ≥ 35 is 
associated with a threefold increased risk of gout. Whether 
the role of these conditions is causal, consequential or an 
epiphenomenon is yet to be determined.3-5
Conversely, gout is an independent risk factor for all-cause 
mortality and cardiovascular morbidity and mortality beyond 
that which would be expected from its strong association 
with traditional co-morbid cardiovascular risk factors. As 
such, gout should be considered as a useful red flag for 
the screening and detection of cardiovascular disease, 
diabetes and kidney disease.5,13
Hyperuricaemia: the primary risk factor 
of gout 
Hyperuricaemia is defined physiologically as a serum urate 
level ≥ 0.38mmol/l, above which physiological saturation 
threshold is exceeded which promotes the deposition 
of MSU crystals in tissues. In the vast majority of cases, 
it arises from under-excretion (90%) and rarely from 
overproduction (10%) of uric acid (Table I).13 Uric acid 
accumulates and precipitates in the form of MSU crystals 
within joint tissues over time, forming complex microtophi. 
Fluxes in uric acid concentrations induce an inflammatory 
cascade that manifests as an acute gout flare.13,14
A common misconception is that hyperuricaemia and 
gout are interchangeable. Only a minority of patients with 
hyperuricaemia develop clinical gout, but increasing serum 
uric acid levels are associated with increased gout risk, such 
that a serum uric acid of ≥ 0.54mmol/l is associated with a 
Table I: Causes of hyperuricaemia
Uric acid under-excretion (90%) Uric acid overproduction
Clinical disorders: Renal failure, hypertension, metabolic syndrome and 
obesity 
Inherited enzyme defects: HGPRT deficiency and
PRPP synthetase overactivity
Nephropathies: Lead nephropathy, polycystic kidney disease, medullary 
cystic kidney disease and familial juvenile hyperuricaemic nephropathy
Increased cell turnover: Myeloproliferative and lymphoproliferative 
disorders, polycythaemia vera, haemolytic disorders and psoriasis 
Drugs increase urate reabsorption through 
trans-stimulation of URAT1: Pyrazinamide and
low-dose salicylate
Purine-rich foods
Agents decreasing renal urate excretion, 
through URAT1 or other mechanisms:
Diuretics, ethambutol, insulin and beta blockers
Drugs: Cytotoxics and warfarin
HGPRT: hypoxanthine-guanine phosphoribosyltransferase, PRPP: 5-phospho-alpha-d-ribosyl pyrophosphate, URAT1: urate transporter 1
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61.1% risk of gout.15,16 Conversely, during an acute attack 
of gout, serum uric acid levels are normal in approximately 
a third of cases. As highlighted above, it is not the absolute 
level of uric acid that precipitates a gout attack. Rather, it is 
the acute changes in the uric acid levels. 
Clinical aspects of gout
The acute attack and intercritical period
After a variable period of months to years of asymptomatic 
hyperuricaemia, gout commonly presents as an acute 
attack of monoarthritis. Classically, it affects the first 
metatarsophalangeal joint, termed 
“podagra”. Less frequent sites include the mid-foot, ankle, 
knee and hand joints. Onset is abrupt, usually in the early 
hours of the morning. It results in an extremely painful 
and tender, red, warm, swollen lower-limb joint. It is often 
clinically difficult to distinguish it from acute septic arthritis. 
In rare instances, more than one joint is affected. The pain 
peaks within 12-24 hours and resolves after days or weeks, 
with or without treatment. Fever, chills and malaise may be 
present. Triggers of an acute attack include trauma, surgery, 
dehydration, an alcohol binge, ingestion of a meal with 
high purine content and drugs that reduce urate excretion. 
Once the acute attack resolves, there is a quiescent period, 
followed by a second attack, usually within two years. 
Subsequent attacks last longer, occur more frequently and 
have atypical features, such as upper-limb and polyarticular 
involvement. The asymptomatic period between attacks is 
referred to as the intercritical period. 
Chronic gouty arthritis
Progression from the initial attack of acute gout to a chronic 
destructive arthropathy generally occurs over a decade of 
poorly controlled hyperuricaemia. It is usually polyarticular. 
Associated deformities in the small hand joints often closely 
mimic rheumatoid arthritis. This stage is characterised 
by low-grade background inflammatory pain. A frequent 
associated feature of this stage is the presence of 
subcutaneous deposits or tophi. Tophi can occur anywhere, 
including the helix of the ear, the olecranon, Achilles tendon, 
over Heberden’s nodes and finger pads. Skin may ulcerate 
and extrude a white, chalky substance. Other more unusual 
sites include the spine, eyes, heart valves and carpal tunnel 
(See Figure 1 a-c).
Diagnosis16-21
Early recognition is imperative to avoid destructive 
complications. Synovial fluid (SF) analysis is the gold 
standard for diagnosis and should be performed whenever 
possible. The presence of negatively birefringent, needle-
shaped MSU crystals confirms the diagnosis of gout, but is 
the basis of diagnosis in only 15% of all cases.5 As mentioned 
previously, an important differential diagnosis to consider in 
a patient with gout presenting with monoarthritis, is septic 
arthritis. This is a medical emergency and can both mimic 
and coexist with gouty arthritis. The SF should always be 
sent for microscopy (Gram stain) and culture when septic 
arthritis is suspected. 
In the primary care setting, joint aspiration is not always 
feasible. In this case, diagnosis is made on clinical 
grounds. The 1977 American Rheumatism Association 
classification developed for research purposes, and the 
more recent 2006 European League Against Rheumatism 
(EULAR) recommendations, are useful guides from which 
the primary care physician can diagnose gout (Tables II and 
III). Efforts are ongoing to improve diagnostic accuracy in 
a nonspecialised setting. Where the diagnosis is uncertain, 
SF analysis is essential and patients should be referred 
appropriately. 
Other important differential diagnoses to consider include 
pseudogout (calcium pyrophosphate deposition disease), 
inflammatory osteoarthritis and pauciarticular presentations 
of systemic rheumatic diseases, including rheumatoid 
arthritis, psoriatic and reactive arthritis.
Uric acid quantification is of limited value in the diagnosis 
of acute gout and is normal in one third of cases. Levels 
should be repeated once an acute attack has subsided. 
Figure 1 a Figure 1 b Figure 1 c
Figures 1 a, b and c: Tophi deposited on first metatarsophalangeal joint and big toe, fingers and helix of the ear 
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Radiography is of limited value in acute gout. In patients 
with longstanding disease, certain characteristic features 
are visible: eccentric soft tissue prominences (tophi) 
and typical erosions (extra-articular, punched-out, with 
overhanging edges and sclerotic rims). Changes are usually 
asymmetrical and affect typical joints. Joint involvement 
and deformity occur much later in the course of the disease 
(Figure 2).
Ultrasonography, computed tomography and magnetic 
resonance imaging are newer available tools for the early 
diagnosis of gout and where atypical sites are affected. 
Ancillary tests include full blood counts (septic arthritis or 
underlying haematological disorder), renal function testing 
and metabolic screening (lipogram and blood glucose). 
Twenty-four hour urine estimation of uric acid is not a 
routine test and should be reserved for specialist use. 
Special subgroups17
Early onset gout
A small subset of patients develop gout at a young age (< 25 
years). Because these patients usually have an underlying 
primary medical condition and tend to present with a more 
accelerated course, early specialist referral is indicated. 
Possible causes include Lesch-Nyhan syndrome or Kelley-
Seegmiller syndrome (enzyme deficiency disorders of 
purine salvage pathway), glycogen storage diseases and 
haematological conditions, such as leukaemias, lymphomas 
and haemoglobinopathies. 
Renal disease 
Renal disease is commonly associated with gout. Renal 
dysfunction can predispose to gout, as seen in patients 
with chronic kidney disease on dialysis. Consequences of 
longstanding hyperuricaemia and gout include acute and 
chronic nephropathy, as well as an increased risk of renal 
calculi: both uric acid and calcium stones.3-5,17
Management22-31
The principles of management include symptom control for 
acute attacks and long-term management in order to prevent 
joint damage and renal complications. This is achieved 
through risk-factor modification and urate-lowering therapy 
(ULT). Management must be individualised and take into 
account potential co-morbid diseases. Current guidelines 
from the British Society of Rheumatology (BSR) and EULAR 
are available to assist with care of patients with gout.22-24
Acute attack
The goal in acute gout is rapid relief of pain, inflammation 
and functional incapacity. Nonsteroidal anti-inflammatory 
agents (NSAIDs))22-25 are the first-line therapy. Initially, where 
possible, maximum doses should be prescribed. Once the 
acute attack subsides, doses can be tapered. Head-to-head 
studies show few differences between various drugs in this 
class. Naproxen is favoured in patients with associated 
cardiovascular disease. A proton-pump inhibitor can be co-
prescribed or selective cyclo-oxygenase 2 inhibitors may be 
used instead in patients with gastrointestinal side-effects, 
like dyspepsia, 
Table II: American College of Rheumatology Classification criteria20
Six of the 11 following criteria:
•	 Maximum inflammation within one day
•	 More than one attack of acute arthritis
•	 Monoarticular arthritis
•	 Redness over joints
•	 Involvement of the first metatarsophalangeal joint 
•	 Unilateral metatarsal joint attack
•	 Unilateral tarsal joint attack
•	 Suspected tophus
•	 Hyperuricaemia
•	 Asymmetric swelling within a joint on X-ray
•	 Subcortical cysts with no erosions on X-ray 
Table III: European League Against Rheumatism 2006 
recommendations for the clinical diagnosis of gout
In acute attacks, the rapid development of severe pain, swelling 
and tenderness that reaches its maximum within just 6-12 hours, 
especially with overlying erythema, is highly suggestive of crystal 
inflammation, although not specific to gout.
A clinical diagnosis alone is reasonably accurate, but not definitive 
without crystal confirmation with regard to typical presentations of 
gout, such as recurrent podagra with hyperuricaemia.
Figure 2: Plain radiograph of the fingers showing typical punched-out 
erosion, overhanging edges (left) and eccentric soft-tissue swelling 
with secondary osteoarthritis of the middle digit
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In cases where NSAIDs are contraindicated, such as 
the elderly, patients with renal or peptic ulcer disease, 
corticosteroids are indicated. Joint aspiration and intra-
articular steroid injection (IAS) is highly effective, providing 
rapid relief of pain and inflammation. Where multiple joints 
are affected or if joints are not amenable to IAS, intramuscular 
methyl prednisolone (160 mg) or oral steroids can be used. 
Prednisone at doses of 30-40 mg/day for five days with a 
gradual tapering over 10-14 days has been shown to be as 
effective as NSAIDs. Importantly, oral corticosteroid use is 
reserved strictly for refractory cases or where NSAIDs are 
contraindicated.22-25
Colchicine in high doses (1 mg stat followed by 0.5 mg every 
3-4 hours, up to a maximum of 3 mg/day), although effective 
for the acute management of gout, is seldom prescribed 
today because of the associated acute gastrointestinal 
toxicity, abdominal cramps and diarrhoea: “Makes you run 
before you can walk”.22,26 
During an acute attack, no attempt should be made to 
alter serum uric acid levels. Hence, ULT (most commonly 
allopurinol) should not be started in patients who are not on 
ULT and the dose of ULT should not be altered.
Adjuncts to medical management
Resting the affected joint and the use of ice packs may be 
helpful.22,23 
Newer drug treatments
Crystal stimulation of interleukin-1 is integral to the 
inflammatory attack on synovial joints. Anti- interleukin-1 
drugs (rilonacept, canakinumab and anakinra) have been 
shown to be effective in refractory cases, with a low side-
effect profile. Due to the high cost and availability of effective 




Patient education and risk-factor modification22-25,27 
Patient education and risk-factor modification is essential 
for all stages of gout management. 
Important areas of lifestyle and risk modification include:
•	 Weight reduction: This should be controlled and gradual 
as crash diets can precipitate acute attacks. 
•	 Increasing fluid intake to produce > 2 l urine per day.
•	 Diet modification: Alcohol, particularly beer, must be 
restricted, high-purine-content meats (red meat and 
organ meat) and seafoods (shellfish) consumption 
should be reduced, fructose-sweetened drinks should 
be avoided and low-fat dairy products encouraged.
•	 Considering vitamin C supplementation (500 mg- 
2 000 mg daily, in divided doses): Caution must be taken 
when prescribing high doses of vitamin C due to the 
low gastrointestinal tolerability and risk of renal calculi 
formation.4,27,30,31 
•	 Where possible, substituting drugs that cause 
hyperuricaemia: Taking low-dose aspirin for 
cardioprotection should not be stopped. 
Pharmacological therapy
Indications for ULT include:
•	 Two attacks/year
•	 The presence of tophi
•	 Destructive changes on plain X-rays 
•	 Renal complications of calculi or urate nephropathy.
Currently, there is no evidence to support the use of ULT 
for asymptomatic hyperuricaemia, except in patients with a 
strong family history of gout.22-24
Treat to urate target
The aim of therapy is to decrease uric acid levels below the 
physiological saturation threshold of ≤ 0.35 mmol/l and more 
refractory cases to < 0.3 mmol/l.22-24 This prevents further 
acute attacks, joint damage and systemic complications. 
With time, this will shrink tophi. 
During patient consultation, decisions should be made 
regarding long-term ULT and emphasis placed on 
adherence to drug therapy. Patients at high risk of non-
adherence, especially younger recently diagnosed male 
patients, should be specifically targeted.
Allopurinol, a xanthine oxidase inhibitor, is the drug of 
choice and prevents the conversion of xanthine to uric acid. 
It should be introduced one to two weeks following an acute 
attack, at a low dose (100 mg nocte), slowly increasing at 
100 mg increments, while monitoring serum urate levels 
four weekly. This assists in reducing flare risk with ULT 
initiation. The most commonly prescribed dose of 300 mg 
is inadequate in reaching the target uric acid level in two 
thirds or more patients. Therefore, doses need to be titrated 
up, with cautious monitoring of renal function and adverse 
effects, up to a dose of 700-900 mg daily. Once target urate 
level is reached, less frequent monitoring is appropriate 
(6-12 monthly). 
Common adverse effects include rashes, deranged liver 
function tests and bone marrow suppression. A life-
threatening hypersensitivity reaction (fever, malaise, a severe 
erythema multiforme rash and multi-organ failure) occurs 
mostly in the elderly and in patients with renal dysfunction. 
The dose should be adjusted for renal dysfunction, with a 
starting dose of 50 mg and similar increments. The most 
important adverse effect of any ULT is the precipitation of 
acute flares. Patients should be reassured of this prior to 
initiation of therapy.14,22-25 
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Colchicine at a dose of 0.5mg twice daily or 0.5 mg daily, or 
a NSAID for six months after initiating ULT, reduces the risk 
of gout flares. Colchicine acts by suppressing urate crystal-
induced activation of NALP3 inflammasome. Potential 
colchicine toxicities include neuromyopathy and bone 
marrow suppression. Toxicity is enhanced by concomitant 
use of erythromycin or statin therapy.25
When to refer to a rheumatologist?
Referral to a rheumatologist is sometimes necessary:
•	 Allopurinol hypersensitivity or gout refractory to maximal 
doses: In these cases, an alternative ULT is to be tried. 
Probenecid is the only uricosuric drug that is available 
locally. Several alternative drugs are either in development 
or have been registered for clinical use in other parts of 
the world, including febuxostat (a non-purine xanthine 
oxidase inhibitor), and a pegalated uricase, pegloticase. 
Losartan has a weak uricosuric effect in patients with 
hypertension. 
•	 Allopurinol desensitisation: Allopurinol desensitation 
for mild intolerance should only be attempted by a 
specialist.22
•	 Young patients, patients with renal disease, and patients 
with extensive tophi: These patients require specialist 
care. 
Key points
•	 Gout prevalence and clinical complexity is on the rise.
•	 Gout is a major cause of disability.
•	 Multiple risk factors are implicated in gout.
•	 Hyperuricaemia is the most important risk factor.
•	 Not all individuals with hyperuricaemia develop gout.
•	 Hyperuricaemia and gout should serve as a red flag for 
cardiovascular risk factors and morbidity.
Conclusion
Gouty arthritis is increasingly common. The majority of 
patients present to general practice. The general practitioner 
should have a good working understanding of this condition 
in order to meet the needs the patient. Patient co-operation 
is integral to the effective management of gout. Specialist 
referral is indicated for certain patient subgroups and in 
treatment-refractory or treatment-intolerant cases. Exciting 
new drugs are being developed and this has revitalised 
interest in this ancient disease. Gout cure can be achieved 
if the treat-to-a-target principle is followed. 
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